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Primary ciliary dyskinesia (PCD) is an autosomal recessive, rare,
genetically heterogeneous condition characterized by oto-sino-
pulmonary disease together with situs abnormalities (Kartagener
syndrome) owing to abnormal ciliary structure and function. Most
patients are currently diagnosed with PCD based on the presence of
defective ciliary ultrastructure. However, diagnosis often remains
challenging due to variability in the clinical phenotype and ciliary
ultrastructural changes. Some patients with PCD have normal ciliary
ultrastructure, which further confounds the diagnosis. A genetic test
for PCD exists but is of limited value because it investigates only
a limited number of mutations in only two genes. The genetics of
PCD is complicated owing to the complexity of axonemal structure
that is highly conserved through evolution, which is comprised of
multiple proteins. Identifying a PCD-causing gene is challenging due
to locus and allelic heterogeneity. Despite genetic heterogeneity,
multiple tools have been used, and there are 11 known PCD-causing
genes. All of these genes combined explain approximately 50% of
PCD cases; hence, more genes need to be identified. This review
briefly describes the current knowledge regarding the genetics of
PCD and focuses on the methodologies used to identify novel PCD-
causing genes, including a candidate gene approach using model
organisms, next-generation massively parallel sequencing tech-
niques, and the use of genetically isolated populations. In conclu-
sion, we demonstrate the multipronged approach that is necessary
to circumvent challenges due to genetic heterogeneity to uncover
genetic causes of PCD.
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Defective ciliary or flagellar structure and function leads to
primary ciliary dyskinesia (PCD) (MIM 242650), which has
several clinical manifestations, including chronic rhinosinusitis,
otitis media, bronchitis, pneumonia, bronchiectasis, male infer-
tility, and reduced fertility in female patients (1–3). Approxi-
mately 50% of patients with PCD have situs inversus totalis
(termed Kartagener syndrome, MIM244400), and situs ambiguus
occurs in at least 6% of patients with PCD (4). PCD is a rare,
genetically heterogeneous, autosomal recessive disorder with an
estimated incidence of approximately 1 in 16,000 to 20,000. There
is no gender, racial, or geographical bias; however, certain geo-
graphically isolated communities or ethnic groups may have
a higher prevalence of PCD due to inbreeding (5, 6). Further
details concerning the clinical manifestations and diagnostic
testing for PCD are discussed in accompanying articles in this
issue of the Journal.
In this session, ‘‘The Emerging Genetics of Primary Ciliary
Dyskinesia,’’ Dr. Maimoona Zariwala from the University of
North Carolina at Chapel Hill began by summarizing the current
knowledge about the genetics of PCD and emphasizing that
the latest exome-capture and massively parallel sequencing tech-
nologies will assist in unraveling the genetic basis of PCD. Dr.
Heymut Omran from the Universitätsklinikum Münster followed
with a presentation describing two novel PCD-causing genes that
were identified using a candidate gene approach. Dr. Thomas
Ferkol from Washington University in St. Louis concluded the
session by discussing the role of genetically isolated populations,
such as the Amish, in identifying novel PCD genes and possible
studies of genotype–phenotype correlations in this cohort. We
summarize all three presentations in this article and discuss areas
that require further investigation. This article begins with the
presentation by Dr. Omran, followed by the presentations by Dr.
Ferkol and Dr. Zariwala. Furthermore, some of the data presented
by Dr. Omran (7, 8) and Dr. Ferkol have been previously published
(5).
OVERVIEW OF PCD GENETICS
Due to genetic, phenotypic, and ciliary ultrastructural heteroge-
neity, the diagnosis of PCD remains challenging. Although
certain diagnostic techniques are available, they are time- and
labor intensive and require special training or reagents and hence
are performed only at a few specialized centers. Ciliary ultra-
structural analysis is useful if axonemal defects are present, but
28% of patients with PCD have normal axonemal ultrastructure
(9), which confounds the diagnosis. In fact, mutations in
DNAH11, a gene that encodes dynein axonemal heavy chain
11, occur in a subset of patients with PCD who present with
normal ciliary ultrastructure; therefore, genetic testing is critical
for the diagnosis in such cases. Although a PCD clinical genetic
test exists in the United States, it only interrogates a few
mutations in DNAI1 and DNAH5, providing limited value (1–
3). More comprehensive testing is offered internationally.
The genetics of PCD is complicated, which reflects the
evolutionarily conserved and complex axonemal structure, which
is comprised of multiple proteins. Ciliary structure is reviewed by
Ostrowski and colleagues in this issue of the Journal (pp. 423).
PCD-causing mutations have been identified in 11 genes, encod-
ing a variety of axonemal components, including the two latest
genes described in this session (Table 1) (1–3, 7, 8). Mutations in
two genes (DNAI1 and DNAH5) that code for ciliary outer
dynein arm proteins are the most common genetic causes of PCD
(18–30% of PCD), but mutations in the remaining genes are
relatively uncommon. Together, mutations in all 11 genes explain
approximately 50% of all cases of PCD (reviewed in References
3, 10, and 11).
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Identifying PCD-causing genes is challenging due to locus
heterogeneity; hence, conventional family-based, genome-wide
linkage studies have not been successful (12). Candidate gene
testing and homozygosity mapping alone or in combination
have resulted in the identification of multiple PCD-causing
genes, including the two novel genes reported in this session.
However, these methods require a large inbred kindred and the
ability to select pertinent candidate genes. Recent advances in
next-generation, high-throughput (massively parallel) sequenc-
ing technology provides opportunities to screen multiple loci
simultaneously to define the etiology of a genetic disorders (13).
This technology is promising for genetically heterogeneous
disorders such as PCD. Defining additional PCD-causing genes
will be helpful for genetic diagnosis and for the development of
a genetic screening test using massively parallel sequencing
technology.
NOVEL PCD VARIANTS CHARACTERIZED BY ABNORMAL
DYNEIN REGULATORY COMPLEX FUNCTION
PCD-causing genetic defects have been mainly characterized as
defects in outer dynein arms (ODA) or the ODA1Inner dynein
arms (IDA) and the central pair apparatus. Recently, a novel
group of PCD variants was identified in patients with character-
istic changes in ciliary ultrastructure, including a reduced number
of inner dynein arms, eccentric central pairs, abnormal alignment
of outer doublets, and occasional displacement of outer doublets.
These mutant respiratory cilia have a beating pattern with
severely reduced amplitude and very rigid axonemes that appear
to be very stiff and straight. The clinical phenotype of this novel
variant PCD is compatible with classic PCD phenotype, including
chronic airways disease with bronchiectasis, randomization of
left–right asymmetry, and immotile sperm tails.
Based on candidate approaches in dog, fish, and mouse models
of variant PCD, the genes CCDC39 and CCDC40 were identified
as candidate genes for PCD (7, 8). Mutational analyses of patients
with PCD identified recessive loss-of-function mutations in
CCDC39 and CCDC40 in 13 and 60% of affected patients,
respectively (7, 8). High-resolution immunofluorescence analyses
of mutant respiratory cilia from patients with CCDC39 and
CCDC40 found an absence of the dynein regulatory complex
(DRC) component, GAS11, and the inner dynein arm light chain,
DNALI1, from the ciliary axonemes. Both genes encode for
uncharacterized, coiled-coil, domain-containing proteins.
FAP59, the orthologue of CCDC39 in Chlamydomonas, was
predicted to be essential for ciliary motility because orthologues
do not exist in nonciliated organisms (14). CCDC39 is normally
localized along the whole respiratory ciliary axoneme and is
absent from cilia in patients with CCDC39 and CCDC40 muta-
tions. Based on these findings, it is very likely that these two
proteins interact with each other. It is possible that both CCDC
proteins physically interact with other axonemal components and
serve as a structural part of the axoneme, possibly as a new DRC
component. This is consistent with findings that mutations in
genes encoding DRC components in Chlamydomonas, such as
PF2, cause a similar ultrastructural phenotype in flagella, in-
cluding the failure to assemble the DRC and the DNALI1-
containing inner dynein arms (15–17). As proposed for PF2,
CCDC39 and CCDC40 could therefore encode for proteins
involved in the stability of the DRC complex by interacting with
one or several DRC subunits. Alternatively, it is possible that
CCDC39 and CCDC40 are important for the cytoplasmic pre-
assembly of axonemal proteins or axonemal targeting and trans-
port of the axonemal components GAS11 and DNALI1 because
they were also found in the apical cytoplasm. However, nothing is
known about the process of cytoplasmic preassembly and axone-
mal targeting and delivery of DRC complexes.
PCD GENES: LESSONS FROM THE AMISH
The Old-Order Amish Mennonite Church communities present
unique opportunities for genetic research. In the seventeenth
century, the Amish and Mennonite churches were established in
Switzerland during the Reformation, and many members emi-
grated to the United States in the eighteenth and nineteenth
centuries to flee religious persecution. First settling in rural
Pennsylvania, close-knit agrarian Amish communities have spread
across North America. Amish settlements in the Midwest have
greatly increased in size and number during the past century. These
communities maintain strict adherence to religious customs.
Because members rarely marry outside the church, consanguinity
is common, resulting in closed populations with a high frequency of
genetic disorders. Intermarriage, relative isolation, and detailed
record-keeping make Amish communities ideal for genetic studies.
We found several children and adults in geographically dispersed
Amish communities with PCD (5) and hypothesized that addi-
TABLE 1. GENES THAT CAUSE PRIMARY CILIARY DYSKINESIA
Human Gene Axonemal Component
Ciliary Ultrastructure of Patients with
PCD with Biallelic Mutations OMIM*
DNAH5 ODA-HC ODA defects 603335
DNAH11 ODA-HC Normal 603339
DNAI1 ODA IC ODA defects 604366
DNAI2 ODA IC ODA defects 605483
TXNDC3 ODA LC/IC Partial ODA defects† 607421
KTU Cytoplasmic‡ ODA1IDA defects 612517
LRRC50 Cytoplasmic‡ ODA1IDA defects 613190
RSPH4A RSH Tx and CP defects 612647
RSPH9 RSH CP defects or normal 612648
CCDC39 DRC Microtubule disorganizationx Current{
CCDC40 DRC Microtubule disorganizationx Current{
Definition of abbreviations: CP 5 central pair; HC 5 heavy chain; IC 5 intermediate chain; IDA 5 inner dynein arm; LC 5 light chain; ODA 5 outer dynein arm;
PCD 5 primary ciliary dyskinesia; RS 5 radial spoke head; Tx 5 transposition.
* OMIM web resource: http://www.ncbi.nlm.nih.gov/Omim/
† Partial defect with approximately two thirds of cilia with shortened or absent and one third with normal ODA.
‡ Cytoplasmic proteins required for the dynein arms assembly.
x Microtubule disorganization characterized by reduced number of IDA, eccentric CP, abnormal alignment of outer doublets, and occasional displacement of
outer doublet.
{ Recent studies presented in this conference and no OMIM numbers assigned yet.
Zariwala, Omran, and Ferkol: The Genetics of PCD 431
tional evaluation would confirm a high frequency of PCD in these
communities and identify a founder mutation.
Our studies identified nine Amish subjects (within seven
subfamilies) who had an unequivocal diagnosis of PCD based
on clinical history (situs inversus totalis, neonatal respiratory
distress, recurrent pneumonia, chronic sinusitis, or male infertil-
ity), reduced nasal nitric oxide values, and ultrastructural defects
of the ciliary axoneme consistent with the diagnosis (ODA
defect) (3, 5, 18). Initially, analyses for known mutations in
DNAI1 and DNAH5 were performed on affected individuals
and family members. Three affected patients from three sub-
families were heterozygous for the DNAI1 (IVS112_3insT)
mutation (5, 19), but full coding gene sequencing did not reveal
the second mutant allele. Haplotype analysis of DNAI1 failed to
reveal evidence of concordance for the second allele in any of
these patients, indicating another gene as causative. A single
subfamily harbored a mutation on exon 63 (10815dT) of DNAH5,
a founder mutation associated with PCD (20). Thus, we found
mutations in two PCD-causing genes in an inbred Amish-
Mennonite cohort, but most subjects have an unidentified novel
genetic defect.
Intragenic single nucleotide polymorphism (SNP) and micro-
satellite genotyping confirmed that DNAI1, DNAH5, and seven
other candidate genes (DNAH11, DNAH7, DNAH9, DNAI2,
DNAL4, DNAH3, and TCTEL1) were not linked to PCD in the
remaining family members. GeneChip Genome-Wide Human
SNP Array 6.0 identified a region of interest on chromosomes 12
(88,373,816–88,974,238) and 13 (48,516,791–49,056,026), which
included candidate genes associated with ciliary or flagellar
defects in patients, or Chlamydomonas. Exome sequencing using
next-generation technology is underway.
In summary, we discovered that a high prevalence of PCD
exists in Amish settlements, likely related to consanguinity
inherent in this population. Although a new DNAH5 mutation
was identified in several members of geographically dispersed
Amish communities, it did not cause PCD in the majority of
subjects studied, which implies that a different disease-causing
gene mutation is present in these families. Indeed, this large
Amish family had surprising genetic heterogeneity, which could
allow us to pursue genotype–phenotype relationships in the
community.
EXOME-CAPTURE AND MASSIVELY PARALLEL
SEQUENCING FOR PCD
Massively parallel sequencing technology, otherwise known as
next-generation sequencing, can be used to capture regions of
interest, including known and potential candidate genes for PCD,
the ciliome (. 1,000 axonemal genes obtained by proteomic
analysis), the exome (all coding exons and splice junctions for all
the known genes in the genome, which is approximately 1% of the
genome), or the entire genome. This technology is useful in
genetically heterogeneous disorders because no prior knowledge
of candidate genes or pathways is necessary. Multiple platforms
for the capture and sequencing technologies are available (21).
This technology produces a massive dataset; therefore, data
analysis requires sophisticated bioinformatics tools and availabil-
ity of the DNA from the family members to validate variants of
interest.
Due to the extensive locus heterogeneity of PCD, we used
whole-exome capture using Nimblegen (CCDS2008 gene set;
Roche NimbleGen Inc., Madison, WI) coupled with paired-end
(massively parallel) sequencing and an Illumina GA2X analyzer
(Illumina Inc., San Diego, CA) to test for novel genes and
mutations in well phenotyped patients with PCD. These patients
were subgrouped by ultrastructural defects and included
defective ODA, IDA alone or combined, defective radial spokes
and central apparatus, acilia/oligo cilia, and normal ciliary
ultrastructure with the compatible clinical phenotype and low
levels of nasal nitric oxide. For each patient, we obtained an
average of approximately 17,000 base substitutions and approx-
imately 500 insertions or deletions. Preliminary data analysis has
revealed biallelic mutations in six unrelated patients in RSPH9,
DNAI2, and DNAH5 genes, previously known to be causing PCD
(20, 22–24). A homozygous loss-of-function mutation was dis-
covered in RSPH9 in a patient with PCD and normal ciliary
ultrastructure. Three unrelated patients with PCD and ODA
defects harbored a novel homozygous stop mutation in DNAI2.
All three patients had Jewish ethnicity, and haplotype analysis
suggested a founder effect. Identification of this novel founder
mutation suggests that mutations in DNAI2 may be more
prevalent in subjects of Jewish ethnicity. Two unrelated patients
with PCD and ODA defects had compound heterozygous
mutations in DNAH5. One of the DNAH5 mutations was
previously missed by Sanger sequencing. Further analysis of that
sample revealed the presence of SNP in one of the PCR primers
causing no amplification of the allele carrying SNP (allele drop-
out). These observations show that mutations can be identified
using exome capture and massively parallel sequencing technol-
ogy. Additionally, mutations may be discovered in a gene that has
previously been tested using standard Sanger sequencing and
deemed negative. In summary, exome sequencing can define
novel disease-causing mutations for genetically heterogeneous
disorders such as PCD.
FUTURE DIRECTIONS
In a breakout session entitled ‘‘Defining PCD Genes and Gene
Mutations through Global Networking,’’ a working group dis-
cussed the following topics: (1) data analysis strategies for next-
generation sequencing technologies, (2) using next-generation
sequencing in patients born to consanguineous union or families
with multiple affected siblings, (3) prioritization of variants
identified in next-generation sequencing technologies, and (4)
the global effort needed to tackle genetic heterogeneity and
reduce duplication of efforts.
Next-generation sequencing technologies interrogate millions
of bases in parallel but produce a large number of variants, which
need to be validated before it is deemed useful. For topic 1, we did
not come up with a final proposal but agreed that massive data
analysis has limitations because each of the current methods has
caveats with respect to the sequence coverage and data filters. We
agreed that stringent filters are useful initially to reduce the
number of variants that require validation, but, in many cases,
nonstringent filters may be needed to ascertain that the gene of
interest is not lost due to high stringency criteria. For topic 2, we
recognized that using one affected individual from a family poses
challenges with data analysis; hence, multiple affected sibs or
a patient with known parental consanguinity may be more useful.
It was suggested that using a SNP chip before exome capture
might be helpful to identify regions of homozygosity (useful for
inbred pedigrees) and regions of concordant genotypes (in an
affected sib-pair), which could be used to direct final next-
generation sequence data analysis (25). For topic 3, we agreed
that multiple variants from exome capture, as well as missense
variants and variants of uncertain significance, can be compared
with the known genes in the same pathways from the model
organisms that can aid with the validation process. For topic 4, we
agreed that global efforts are needed to circumvent the problem
of genetic heterogeneity. Moreover, it is efficient to test each gene
in a large number of patients by collaborating to combine affected
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individuals from multiple groups. This approach will help de-
cipher the mutation frequency data from larger cohort, instead of
multiple groups working on the same gene with a smaller pool of
patients. We also agreed that it would be important to identify
funding sources to assist the global effort to treat this rare
disorder.
CONCLUSIONS
We have demonstrated that multiple strategies can be used to
identify genetic causes of PCD, which is largely a genetically
heterogeneous disorder. Candidate gene analysis continues to
prove useful in identifying novel genes for PCD as mutations in
CCDC39 and CCDC40 caused disease due to abnormal DRC
function. Furthermore, genetically isolated populations, such as
Amish-Mennonites, provide unique opportunities in understand-
ing the genetic basis of complex diseases such as PCD. In addition,
the recent advances in next-generation sequencing technologies
are very promising and have demonstrated novel genetic muta-
tions in patients with PCD. This technology has the potential to
develop a clinical molecular genetic test for PCD by using
targeted capture of all known PCD-causing genes and interro-




Author Disclosure: M.A.Z. does not have a financial relationship with a commer-
cial entity that has an interest in the subject of this manuscript. H.O. received
institutional grant support from Deutsche Forschungsgemeinschaft funding.
T.W.F. received lecture fees from Genentech, Health Matters CME, and the
France Foundation. He received grant support from Gilead, Boehringer Ingel-
heim, the Cystic Fibrosis Foundation, and the Children’s Discovery Institute. He
owns six patents through Case Western Reserve University and is on the ATS
Board of Directors, Chair, Pediatric Assembly. He is a sub-Board member of the
American Board of Pediatrics.
Acknowledgments: The authors thank the PCD patients and their family members;
the US and German PCD Foundation; Drs. Knowles, Leigh, and the PCD group
from the University of North Carolina at Chapel Hill, NC; Drs. Shendure, Nickerson,
and Bamshad and the group from Department of Genome Sciences, University of
Washington, Seattle; all of the investigators and coordinators of the ‘‘Genetic
Disorders of Mucociliary Clearance Consortium (GDMCC),’’ which is part of the
Rare Disease Clinical Research Network (http://rarediseasesnetwork.epi.usf.edu/
gdmcc/index.htm); the PCD group from Washington University, St. Louis, MO and
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